PIIS1201971214017172.pdf (389.88 kB)
Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them
journal contribution
posted on 2023-06-08, 20:29 authored by Dimitrios Evangelopoulos, Joana Diniz da Fonseca, Simon WaddellSimon WaddellTuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The bacterium responsible for this disease, Mycobacterium tuberculosis (M.tb), has successfully survived within hostile host environments, adapting to immune defence mechanisms, for centuries. This has resulted in a disease that is challenging to treat, requiring lengthy chemotherapy with multi-drug regimens. One explanation for this difficulty in eliminating M.tb bacilli in vivo is the disparate action of antimicrobials on heterogeneous populations of M.tb, where mycobacterial physiological state may influence drug efficacy. In order to develop improved drug combinations that effectively target diverse mycobacterial phenotypes, it is important to understand how such subpopulations of M.tb are formed during human infection. We review here the in vitro and in vivo systems used to model M.tb subpopulations that may persist during drug therapy, and offer aspirations for future research in this field.
History
Publication status
- Published
File Version
- Published version
Journal
International Journal of Infectious DiseasesISSN
1201-9712Publisher
ElsevierExternal DOI
Volume
32Page range
76-80Department affiliated with
- Global Health and Infection Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2015-09-02First Open Access (FOA) Date
2015-09-02First Compliant Deposit (FCD) Date
2015-09-02Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC